Patient-reported outcomes show improved quality of life with the nivolumab-ipilimumab combination
Patient-reported outcomes data from the Phase 3 CheckMate-214 trial of [...]
FDA approves nivolumab-ipilimumab combination for advanced kidney cancer
The US Food and Drug Administration (FDA) has granted approval [...]
Ipilimumab-nivolumab combination improves overall survival in metastatic kidney cancer
Overall survival data for the ipilimumab-nivolumab combination versus sunitinib from [...]
EAU guidelines for the treatment of first-line metastatic kidney cancer to be updated
Further to the results from recent studies, particularly CheckMate-214, the [...]
Collaboration to develop a cancer therapy to be used with immune checkpoint inhibitors
Bristol-Myers Squibb and Nektar Therapeutics are working together to develop a cancer therapy [...]
Combination therapies for kidney cancer
The following is a Practice Update interview with Dr Hans Hammers, Associate [...]
The future of immuno-oncology in kidney cancer
In his keynote lecture at the American Society for Clinical [...]
The benefits of immunotherapy combinations
This article, published in Nature just before Christmas, gives a [...]
Sequencing of treatments for advanced kidney cancer remains uncertain
There are now a number of licensed drug options available [...]
European guidelines for the management of metastatic renal cell carcinoma to be updated
The European Association of Urology (EAU) guidelines are to be [...]
